JAK Inhibitor denied due to quantity / dose limits by Cigna?

Cigna's specific coverage criteria for jak inhibitor are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Applies Quantity Limits to JAK Inhibitors — and How to Appeal

Quantity-limit (QL) denials for JAK inhibitors mean Cigna's system has flagged that the quantity or frequency of the prescription exceeds the plan's default supply limit for that drug. These denials are very commonly appealed because clinical circumstances — dose adjustments authorized by the prescriber, split-dose regimens, or a titration schedule — often justify quantities outside the standard limit.

## Why This Denial Happens

Plans set quantity limits based on the most common FDA-approved dosing regimen. When a prescriber orders a quantity that diverges from that default — even for a clinically valid reason such as a different approved dose, a medically supervised titration, or a supply for a longer trip — the automated QL edits trigger a denial. The denial is mechanical, not a clinical judgment about your case.

## Your Appeal Rights

• ERISA §503: you are entitled to the specific quantity-limit policy Cigna applied and a full-and-fair review of your appeal.
• ACA §2719 External Review: available after exhausting internal appeals. The window is approximately four months from final adverse determination — confirm the exact deadline on your denial letter. Expedited external review is available when the clinical situation is urgent.

## Concrete Appeal Process

1. Confirm from the denial letter exactly which quantity limit was applied. 2. Request Cigna's published quantity-limit policy for this drug. 3. Review the FDA-approved prescribing label for the specific JAK inhibitor: it will document all approved dosing regimens. If your prescribed quantity corresponds to an approved dose or regimen, state this explicitly. 4. File the internal appeal with supporting documentation. 5. If denied internally, proceed to external review.

## Documentation to Gather

• FDA prescribing label: identifying the specific approved dosing regimen that corresponds to the prescribed quantity.
• Prescriber justification: a letter from the prescribing physician explaining the clinical reason for the quantity prescribed, tied to the approved label or an applicable specialist-society guideline.
• Pharmacy dispensing record: to confirm what was actually dispensed and what was denied.
• Clinical notes: if the quantity relates to a titration or dose adjustment, chart documentation of the clinical rationale.

## Criteria-Mapping Structure

Obtain the quantity-limit policy. Alongside it, pull the dosing section of the FDA-approved prescribing information. Map each limit criterion to the chart and label evidence. If the prescribed quantity corresponds to an approved regimen, the mapping will show the limit is being applied more restrictively than the FDA label supports — a strong appeal argument.